Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NPD's Cash to Debt is ranked higher than
97% of the 351 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.65 vs. NPD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NPD' s 10-Year Cash to Debt Range
Min: 27.67  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.55
NPD's Equity to Asset is ranked higher than
71% of the 334 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.45 vs. NPD: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
NPD' s 10-Year Equity to Asset Range
Min: 0  Med: 0.63 Max: 0.87
Current: 0.55
0
0.87
Interest Coverage No Debt
NPD's Interest Coverage is ranked higher than
95% of the 241 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.47 vs. NPD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NPD' s 10-Year Interest Coverage Range
Min: 17.73  Med: 10000.00 Max: 9999.99
Current: No Debt
17.73
9999.99
F-Score: 6
Z-Score: 4.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 0.85
NPD's Operating margin (%) is ranked lower than
75% of the 352 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.82 vs. NPD: 0.85 )
Ranked among companies with meaningful Operating margin (%) only.
NPD' s 10-Year Operating margin (%) Range
Min: -2.92  Med: 1.55 Max: 9.25
Current: 0.85
-2.92
9.25
Net-margin (%) 0.03
NPD's Net-margin (%) is ranked lower than
80% of the 352 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.74 vs. NPD: 0.03 )
Ranked among companies with meaningful Net-margin (%) only.
NPD' s 10-Year Net-margin (%) Range
Min: -2.75  Med: 0.74 Max: 8.04
Current: 0.03
-2.75
8.04
ROE (%) 0.13
NPD's ROE (%) is ranked lower than
82% of the 343 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.22 vs. NPD: 0.13 )
Ranked among companies with meaningful ROE (%) only.
NPD' s 10-Year ROE (%) Range
Min: -8215.56  Med: 1.90 Max: 9.01
Current: 0.13
-8215.56
9.01
ROA (%) 0.07
NPD's ROA (%) is ranked lower than
80% of the 353 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.50 vs. NPD: 0.07 )
Ranked among companies with meaningful ROA (%) only.
NPD' s 10-Year ROA (%) Range
Min: -19.18  Med: 1.80 Max: 7.3
Current: 0.07
-19.18
7.3
ROC (Joel Greenblatt) (%) 5.45
NPD's ROC (Joel Greenblatt) (%) is ranked lower than
73% of the 353 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.55 vs. NPD: 5.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NPD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -20.69  Med: 17.76 Max: 122.76
Current: 5.45
-20.69
122.76
Revenue Growth (3Y)(%) 8.30
NPD's Revenue Growth (3Y)(%) is ranked higher than
71% of the 293 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. NPD: 8.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NPD' s 10-Year Revenue Growth (3Y)(%) Range
Min: -11.4  Med: 8.30 Max: 58.6
Current: 8.3
-11.4
58.6
EBITDA Growth (3Y)(%) -31.90
NPD's EBITDA Growth (3Y)(%) is ranked lower than
93% of the 261 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.80 vs. NPD: -31.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NPD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -24.30 Max: 122.4
Current: -31.9
0
122.4
» NPD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

NPD Guru Trades in Q2 2014

Jim Simons 560,600 sh (-11.68%)
» More
Q3 2014

NPD Guru Trades in Q3 2014

Jim Simons 588,200 sh (+4.92%)
» More
Q4 2014

NPD Guru Trades in Q4 2014

Jim Simons 639,422 sh (+8.71%)
» More
Q1 2015

NPD Guru Trades in Q1 2015

Jim Simons 651,500 sh (+1.89%)
» More
» Details

Insider Trades

Latest Guru Trades with NPD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 1123.76
NPD's P/E(ttm) is ranked lower than
100% of the 279 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 23.70 vs. NPD: 1123.76 )
Ranked among companies with meaningful P/E(ttm) only.
NPD' s 10-Year P/E(ttm) Range
Min: 10.41  Med: 71.90 Max: 30787.82
Current: 1123.76
10.41
30787.82
Forward P/E 15.67
NPD's Forward P/E is ranked lower than
51% of the 163 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.38 vs. NPD: 15.67 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 699.80
NPD's PE(NRI) is ranked lower than
100% of the 279 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 23.80 vs. NPD: 699.80 )
Ranked among companies with meaningful PE(NRI) only.
NPD' s 10-Year PE(NRI) Range
Min: 10.43  Med: 63.81 Max: 971.76
Current: 699.8
10.43
971.76
P/B 1.65
NPD's P/B is ranked higher than
56% of the 342 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.96 vs. NPD: 1.65 )
Ranked among companies with meaningful P/B only.
NPD' s 10-Year P/B Range
Min: 0.69  Med: 1.39 Max: 4.86
Current: 1.65
0.69
4.86
P/S 0.44
NPD's P/S is ranked higher than
55% of the 352 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.52 vs. NPD: 0.44 )
Ranked among companies with meaningful P/S only.
NPD' s 10-Year P/S Range
Min: 0.28  Med: 0.93 Max: 6.71
Current: 0.44
0.28
6.71
EV-to-EBIT 41.37
NPD's EV-to-EBIT is ranked lower than
90% of the 296 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.65 vs. NPD: 41.37 )
Ranked among companies with meaningful EV-to-EBIT only.
NPD' s 10-Year EV-to-EBIT Range
Min: -1481  Med: 23.30 Max: 144.2
Current: 41.37
-1481
144.2
Shiller P/E 42.09
NPD's Shiller P/E is ranked lower than
82% of the 210 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 23.69 vs. NPD: 42.09 )
Ranked among companies with meaningful Shiller P/E only.
NPD' s 10-Year Shiller P/E Range
Min: 10.13  Med: 21.50 Max: 63.6
Current: 42.09
10.13
63.6
Current Ratio 2.03
NPD's Current Ratio is ranked higher than
79% of the 336 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.21 vs. NPD: 2.03 )
Ranked among companies with meaningful Current Ratio only.
NPD' s 10-Year Current Ratio Range
Min: 1.17  Med: 2.58 Max: 6.94
Current: 2.03
1.17
6.94
Quick Ratio 1.13
NPD's Quick Ratio is ranked higher than
74% of the 336 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.75 vs. NPD: 1.13 )
Ranked among companies with meaningful Quick Ratio only.
NPD' s 10-Year Quick Ratio Range
Min: 0.49  Med: 1.75 Max: 6.33
Current: 1.13
0.49
6.33
Days Inventory 115.25
NPD's Days Inventory is ranked lower than
92% of the 344 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 37.77 vs. NPD: 115.25 )
Ranked among companies with meaningful Days Inventory only.
NPD' s 10-Year Days Inventory Range
Min: 44.74  Med: 117.94 Max: 122.17
Current: 115.25
44.74
122.17
Days Sales Outstanding 15.13
NPD's Days Sales Outstanding is ranked lower than
56% of the 286 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.39 vs. NPD: 15.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
NPD' s 10-Year Days Sales Outstanding Range
Min: 6.04  Med: 12.97 Max: 17.85
Current: 15.13
6.04
17.85

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 12.66
NPD's Dividend Yield is ranked higher than
98% of the 446 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.86 vs. NPD: 12.66 )
Ranked among companies with meaningful Dividend Yield only.
NPD' s 10-Year Dividend Yield Range
Min: 0.85  Med: 6.18 Max: 18.14
Current: 12.66
0.85
18.14
Yield on cost (5-Year) 12.55
NPD's Yield on cost (5-Year) is ranked higher than
97% of the 445 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.16 vs. NPD: 12.55 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NPD' s 10-Year Yield on cost (5-Year) Range
Min: 0.85  Med: 6.18 Max: 18.14
Current: 12.55
0.85
18.14
Share Buyback Rate 1.50
NPD's Share Buyback Rate is ranked higher than
81% of the 204 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.50 vs. NPD: 1.50 )
Ranked among companies with meaningful Share Buyback Rate only.
NPD' s 10-Year Share Buyback Rate Range
Min: 4.6  Med: 1.50 Max: -27.1
Current: 1.5

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 2.47
NPD's Price/Net Current Asset Value is ranked higher than
77% of the 113 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.55 vs. NPD: 2.47 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NPD' s 10-Year Price/Net Current Asset Value Range
Min: 1.17  Med: 1.88 Max: 5.07
Current: 2.47
1.17
5.07
Price/Tangible Book 1.79
NPD's Price/Tangible Book is ranked higher than
58% of the 307 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.26 vs. NPD: 1.79 )
Ranked among companies with meaningful Price/Tangible Book only.
NPD' s 10-Year Price/Tangible Book Range
Min: 0.96  Med: 1.39 Max: 4.66
Current: 1.79
0.96
4.66
Price/Projected FCF 2.08
NPD's Price/Projected FCF is ranked lower than
67% of the 216 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.45 vs. NPD: 2.08 )
Ranked among companies with meaningful Price/Projected FCF only.
NPD' s 10-Year Price/Projected FCF Range
Min: 1.07  Med: 1.54 Max: 38.3
Current: 2.08
1.07
38.3
Price/Median PS Value 0.49
NPD's Price/Median PS Value is ranked higher than
93% of the 341 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.18 vs. NPD: 0.49 )
Ranked among companies with meaningful Price/Median PS Value only.
NPD' s 10-Year Price/Median PS Value Range
Min: 0.35  Med: 0.94 Max: 6.89
Current: 0.49
0.35
6.89
Price/Graham Number 10.23
NPD's Price/Graham Number is ranked lower than
98% of the 246 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.78 vs. NPD: 10.23 )
Ranked among companies with meaningful Price/Graham Number only.
NPD' s 10-Year Price/Graham Number Range
Min: 0.67  Med: 1.94 Max: 7.95
Current: 10.23
0.67
7.95
Earnings Yield (Greenblatt) (%) 2.37
NPD's Earnings Yield (Greenblatt) (%) is ranked lower than
76% of the 351 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.50 vs. NPD: 2.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NPD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.7  Med: 3.10 Max: 153.9
Current: 2.37
0.7
153.9
Forward Rate of Return (Yacktman) (%) -25.75
NPD's Forward Rate of Return (Yacktman) (%) is ranked lower than
96% of the 219 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.99 vs. NPD: -25.75 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NPD' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -50.8  Med: -25.80 Max: 1.1
Current: -25.75
-50.8
1.1

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:WAG, RAD, PETS, DSCM, CVS, PERF » details
Traded in other countries:4CSA.Germany,
China Nepstar Chain Drugstore Ltd was incorporated in the Cayman Islands in August 2004. The Company operates retail drugstore business. The Company provides professional and convenient pharmacy services and other merchandise, including over-the-counter drugs, nutritional supplements, herbal products, personal care products, family care products, as well as convenience products including consumable, seasonal and promotional items. It also offers private label products. The Company offers 523 nutritional supplements, including a variety of healthcare supplements, vitamins, minerals and dietary products. Its other products include personal care products such as skin care, hair care and beauty products, family care products such as portable medical devices for family use, birth control and early pregnancy test products, and convenience products, including soft drinks, packaged snacks, cleaning agents and stationery. The other products also include seasonal and promotional items tailored to local consumer demand for convenience and quality. The Company also provides ancillary services such as providing free blood pressure measurements in its stores. The Company competes with other retail drugstore chains or independent drugstores. As a distributor and retailer of pharmaceutical products, the Company is subject to regulation and oversight by different levels of the food and drug administration in China, in particular, the State Food and Drug Administration, or the SFDA.
» More Articles for NYSE:NPD

Headlines

Articles On GuruFocus.com
High Yield George Soros Stocks: China Nepstar ADS, Chimera Investment, PDL BioPharma, MFA Mortgage I Apr 22 2010 
BURTON463 note on NPD Mar 11 2010 
BURTON463 note on NPD Mar 11 2010 
BURTON463 note on NPD Mar 11 2010 
China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results Aug 24 2009 
China Nepstar Chain Drugstore Announces Special Dividend Aug 24 2009 
Ron Baron Likes Layne Christensen, Ritchie Brothers Auctioneers, Bankrate and China Nepstar Mar 25 2008 

More From Other Websites
China Nepstar Chain Drugstore Ltd. Announces Formation of Special Committee to Consider "Going... Jul 17 2015
China Nepstar Chain Drugstore Ltd. Announces Formation of Special Committee to Consider "Going... Jul 17 2015
China Stock Roundup: Mindray Medical to Buy Remaining Stake in Dragonbio, Noah Holdings Announces... Jul 09 2015
China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal Jul 06 2015
China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal Jul 06 2015
China Nepstar Chain Drugstore Ltd Earnings Call scheduled for 8:00 am ET today May 26 2015
Q1 2015 China Nepstar Chain Drugstore Ltd Earnings Release - Before Market Open May 26 2015
China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results May 26 2015
China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment May 22 2015
China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment May 22 2015
China Nepstar Chain Drugstore to Report First Quarter 2015 Financial Results on May 26, 2015 May 08 2015
China Nepstar Chain Drugstore to Report First Quarter 2015 Financial Results on May 26, 2015 May 08 2015
CHINA NEPSTAR CHAIN DRUGSTORE LTD. Financials Apr 28 2015
China Nepstar Chain Drugstore Filed 2014 Annual Report on Form 20-F Apr 24 2015
China Nepstar Chain Drugstore Filed 2014 Annual Report on Form 20-F Apr 24 2015
Rite Aid (RAD) Appoints Rempel to Enhance IT Solutions - Analyst Blog Apr 21 2015
Will China Nepstar Chain Drugstore (NPD) Continue to Surge Higher? - Tale of the Tape Apr 10 2015
Rite Aid (RAD) Tops Q4 Earnings and Sales, Guides FY16 - Analyst Blog Apr 09 2015
China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results Mar 30 2015
China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results Mar 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK